Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
31
ANSLF Quote, Financials, Valuation and Earnings
Last price:
$21.05
Seasonality move
:
1.27%
Day range:
$21.05 - $21.05
52-week range:
$18.00 - $25.00
Dividend yield:
0%
P/E ratio:
30.27x
P/S ratio:
1.54x
P/B ratio:
1.38x
Volume:
--
Avg. volume:
955
1-year change:
-10.12%
Market cap:
$3.1B
Revenue:
$2B
EPS (TTM):
$0.70
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ANSLF
Ansell Ltd.
|
-- | -- | -- | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | $12.00 |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | $9.50 |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -- | -- | $19.01 |
|
MESO
Mesoblast Ltd.
|
$23M | -- | -100% | -- | $35.00 |
|
PPCB
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ANSLF
Ansell Ltd.
|
$21.05 | -- | $3.1B | 30.27x | $0.22 | 0% | 1.54x |
|
ATHE
Alterity Therapeutics Ltd.
|
$3.22 | $12.00 | $58.4M | -- | $0.00 | 0% | 3.58x |
|
IMMP
Immutep Ltd.
|
$2.95 | $9.50 | $429.4M | -- | $0.00 | 0% | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
$5.00 | $19.01 | $8.4M | -- | $0.00 | 0% | 225.92x |
|
MESO
Mesoblast Ltd.
|
$18.16 | $35.00 | $2.3B | -- | $0.00 | 0% | 127.45x |
|
PPCB
|
$11.98 | -- | $158.1K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ANSLF
Ansell Ltd.
|
30.23% | 0.759 | -- | 1.04x |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | 2.761 | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | 0.437 | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-6.76% | 4.217 | 5.57% | 0.07x |
|
MESO
Mesoblast Ltd.
|
-- | 2.583 | -- | -- |
|
PPCB
|
-- | 4.794 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ANSLF
Ansell Ltd.
|
-- | -- | 4.48% | 6.21% | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -784.09% | -1083.16% | -- | -- |
|
MESO
Mesoblast Ltd.
|
-- | -- | -- | -- | -- | -- |
|
PPCB
|
-- | -$290.8K | -- | -- | -- | -$235.5K |
Ansell Ltd. vs. Competitors
-
Which has Higher Returns ANSLF or ATHE?
Alterity Therapeutics Ltd. has a net margin of -- compared to Ansell Ltd.'s net margin of --. Ansell Ltd.'s return on equity of 6.21% beat Alterity Therapeutics Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ANSLFAnsell Ltd.-- -- $2.7B ATHEAlterity Therapeutics Ltd.-- -- -- -
What do Analysts Say About ANSLF or ATHE?
Ansell Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Alterity Therapeutics Ltd. has an analysts' consensus of $12.00 which suggests that it could grow by 289.61%. Given that Alterity Therapeutics Ltd. has higher upside potential than Ansell Ltd., analysts believe Alterity Therapeutics Ltd. is more attractive than Ansell Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ANSLFAnsell Ltd.0 0 0 ATHEAlterity Therapeutics Ltd.0 0 0 -
Is ANSLF or ATHE More Risky?
Ansell Ltd. has a beta of 0.469, which suggesting that the stock is 53.092% less volatile than S&P 500. In comparison Alterity Therapeutics Ltd. has a beta of 0.065, suggesting its less volatile than the S&P 500 by 93.549%.
-
Which is a Better Dividend Stock ANSLF or ATHE?
Ansell Ltd. has a quarterly dividend of $0.22 per share corresponding to a yield of 0%. Alterity Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ansell Ltd. pays 71.92% of its earnings as a dividend. Alterity Therapeutics Ltd. pays out -- of its earnings as a dividend. Ansell Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ANSLF or ATHE?
Ansell Ltd. quarterly revenues are --, which are smaller than Alterity Therapeutics Ltd. quarterly revenues of --. Ansell Ltd.'s net income of -- is lower than Alterity Therapeutics Ltd.'s net income of --. Notably, Ansell Ltd.'s price-to-earnings ratio is 30.27x while Alterity Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ansell Ltd. is 1.54x versus 3.58x for Alterity Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANSLFAnsell Ltd.1.54x 30.27x -- -- ATHEAlterity Therapeutics Ltd.3.58x -- -- --
-
Which has Higher Returns ANSLF or IMMP?
Immutep Ltd. has a net margin of -- compared to Ansell Ltd.'s net margin of --. Ansell Ltd.'s return on equity of 6.21% beat Immutep Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ANSLFAnsell Ltd.-- -- $2.7B IMMPImmutep Ltd.-- -- -- -
What do Analysts Say About ANSLF or IMMP?
Ansell Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Immutep Ltd. has an analysts' consensus of $9.50 which suggests that it could grow by 222.03%. Given that Immutep Ltd. has higher upside potential than Ansell Ltd., analysts believe Immutep Ltd. is more attractive than Ansell Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ANSLFAnsell Ltd.0 0 0 IMMPImmutep Ltd.1 0 0 -
Is ANSLF or IMMP More Risky?
Ansell Ltd. has a beta of 0.469, which suggesting that the stock is 53.092% less volatile than S&P 500. In comparison Immutep Ltd. has a beta of 1.758, suggesting its more volatile than the S&P 500 by 75.781%.
-
Which is a Better Dividend Stock ANSLF or IMMP?
Ansell Ltd. has a quarterly dividend of $0.22 per share corresponding to a yield of 0%. Immutep Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ansell Ltd. pays 71.92% of its earnings as a dividend. Immutep Ltd. pays out -- of its earnings as a dividend. Ansell Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ANSLF or IMMP?
Ansell Ltd. quarterly revenues are --, which are smaller than Immutep Ltd. quarterly revenues of --. Ansell Ltd.'s net income of -- is lower than Immutep Ltd.'s net income of --. Notably, Ansell Ltd.'s price-to-earnings ratio is 30.27x while Immutep Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ansell Ltd. is 1.54x versus -- for Immutep Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANSLFAnsell Ltd.1.54x 30.27x -- -- IMMPImmutep Ltd.-- -- -- --
-
Which has Higher Returns ANSLF or KZIA?
Kazia Therapeutics Ltd. has a net margin of -- compared to Ansell Ltd.'s net margin of --. Ansell Ltd.'s return on equity of 6.21% beat Kazia Therapeutics Ltd.'s return on equity of -1083.16%.
Company Gross Margin Earnings Per Share Invested Capital ANSLFAnsell Ltd.-- -- $2.7B KZIAKazia Therapeutics Ltd.-- -- -$6.3M -
What do Analysts Say About ANSLF or KZIA?
Ansell Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Kazia Therapeutics Ltd. has an analysts' consensus of $19.01 which suggests that it could grow by 280.88%. Given that Kazia Therapeutics Ltd. has higher upside potential than Ansell Ltd., analysts believe Kazia Therapeutics Ltd. is more attractive than Ansell Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ANSLFAnsell Ltd.0 0 0 KZIAKazia Therapeutics Ltd.1 0 0 -
Is ANSLF or KZIA More Risky?
Ansell Ltd. has a beta of 0.469, which suggesting that the stock is 53.092% less volatile than S&P 500. In comparison Kazia Therapeutics Ltd. has a beta of 1.739, suggesting its more volatile than the S&P 500 by 73.892%.
-
Which is a Better Dividend Stock ANSLF or KZIA?
Ansell Ltd. has a quarterly dividend of $0.22 per share corresponding to a yield of 0%. Kazia Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ansell Ltd. pays 71.92% of its earnings as a dividend. Kazia Therapeutics Ltd. pays out -- of its earnings as a dividend. Ansell Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ANSLF or KZIA?
Ansell Ltd. quarterly revenues are --, which are smaller than Kazia Therapeutics Ltd. quarterly revenues of --. Ansell Ltd.'s net income of -- is lower than Kazia Therapeutics Ltd.'s net income of --. Notably, Ansell Ltd.'s price-to-earnings ratio is 30.27x while Kazia Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ansell Ltd. is 1.54x versus 225.92x for Kazia Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANSLFAnsell Ltd.1.54x 30.27x -- -- KZIAKazia Therapeutics Ltd.225.92x -- -- --
-
Which has Higher Returns ANSLF or MESO?
Mesoblast Ltd. has a net margin of -- compared to Ansell Ltd.'s net margin of --. Ansell Ltd.'s return on equity of 6.21% beat Mesoblast Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ANSLFAnsell Ltd.-- -- $2.7B MESOMesoblast Ltd.-- -- -- -
What do Analysts Say About ANSLF or MESO?
Ansell Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Mesoblast Ltd. has an analysts' consensus of $35.00 which suggests that it could grow by 92.73%. Given that Mesoblast Ltd. has higher upside potential than Ansell Ltd., analysts believe Mesoblast Ltd. is more attractive than Ansell Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ANSLFAnsell Ltd.0 0 0 MESOMesoblast Ltd.1 0 0 -
Is ANSLF or MESO More Risky?
Ansell Ltd. has a beta of 0.469, which suggesting that the stock is 53.092% less volatile than S&P 500. In comparison Mesoblast Ltd. has a beta of 2.140, suggesting its more volatile than the S&P 500 by 113.996%.
-
Which is a Better Dividend Stock ANSLF or MESO?
Ansell Ltd. has a quarterly dividend of $0.22 per share corresponding to a yield of 0%. Mesoblast Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ansell Ltd. pays 71.92% of its earnings as a dividend. Mesoblast Ltd. pays out -- of its earnings as a dividend. Ansell Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ANSLF or MESO?
Ansell Ltd. quarterly revenues are --, which are smaller than Mesoblast Ltd. quarterly revenues of --. Ansell Ltd.'s net income of -- is lower than Mesoblast Ltd.'s net income of --. Notably, Ansell Ltd.'s price-to-earnings ratio is 30.27x while Mesoblast Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ansell Ltd. is 1.54x versus 127.45x for Mesoblast Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANSLFAnsell Ltd.1.54x 30.27x -- -- MESOMesoblast Ltd.127.45x -- -- --
-
Which has Higher Returns ANSLF or PPCB?
has a net margin of -- compared to Ansell Ltd.'s net margin of --. Ansell Ltd.'s return on equity of 6.21% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ANSLFAnsell Ltd.-- -- $2.7B PPCB-- -$0.00 -- -
What do Analysts Say About ANSLF or PPCB?
Ansell Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Ansell Ltd. has higher upside potential than , analysts believe Ansell Ltd. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings ANSLFAnsell Ltd.0 0 0 PPCB0 0 0 -
Is ANSLF or PPCB More Risky?
Ansell Ltd. has a beta of 0.469, which suggesting that the stock is 53.092% less volatile than S&P 500. In comparison has a beta of 1.881, suggesting its more volatile than the S&P 500 by 88.104%.
-
Which is a Better Dividend Stock ANSLF or PPCB?
Ansell Ltd. has a quarterly dividend of $0.22 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ansell Ltd. pays 71.92% of its earnings as a dividend. pays out -- of its earnings as a dividend. Ansell Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ANSLF or PPCB?
Ansell Ltd. quarterly revenues are --, which are smaller than quarterly revenues of --. Ansell Ltd.'s net income of -- is lower than 's net income of -$354.3K. Notably, Ansell Ltd.'s price-to-earnings ratio is 30.27x while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ansell Ltd. is 1.54x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANSLFAnsell Ltd.1.54x 30.27x -- -- PPCB-- -- -- -$354.3K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
55
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
45
CTEV alert for Jan 2
Claritev Corp. [CTEV] is down 20.7% over the past day.
Sell
47
ASTS alert for Jan 2
AST Spacemobile, Inc. [ASTS] is up 14.94% over the past day.
Buy
60
BIDU alert for Jan 3
Baidu, Inc. [BIDU] is up 15.01% over the past day.
